Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery
| Autor: | Filippos Triposkiadis, Kiriaki Papageorgiou, Charalampos Parisis, Marios E. Daskalopoulos, Stella S. Daskalopoulou, Georgios I Tagarakis, Isaac Aidonidis, Vassilios T Liouras, Nikolaos Tsilimingas, Ioannis Skoularingis, Paschalis-Adam Molyvdas, V. Simopoulos |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
medicine.medical_specialty Ranolazine Piperazines law.invention Percutaneous Coronary Intervention Postoperative Complications Randomized controlled trial law Internal medicine Atrial Fibrillation Preoperative Care Medicine Humans In patient Single-Blind Method Coronary Artery Bypass Aged Pharmacology Ejection fraction business.industry Atrial fibrillation Middle Aged medicine.disease Coronary revascularization Surgery Clinical trial medicine.anatomical_structure Treatment Outcome Anesthesia Cardiology Acetanilides Female Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Artery medicine.drug |
| Zdroj: | Current vascular pharmacology. 11(6) |
| ISSN: | 1875-6212 |
| Popis: | Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery. Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF. Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different. Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|